In traditional high-risk profiles of breast cancer such as triple-negative and HER2 positive cancers, higher percentage of tumor infiltrating lymphocytes (TILs) are associated with improved clinical outcome [3–5]. This evidence concerns the gene ERBB2 and breast carcinoma.